Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Chiu

Showing results (61-70 of 129) with videos related to

Pageof 13
Sort By:
BMC Bioinformatics|March 8, 2020
CNV Radar: an improved method for somatic copy number alteration characterization in oncologyDavid Soong, Jeran Stratford, Herve Avet-Loiseau, et al.
Oncoimmunology|February 8, 2021
Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phagocytosisSerika D Naicker, Claire L Feerick, Kevin Lynch, et al.
Blood|June 23, 2017
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myelomaAjai Chari, Attaya Suvannasankha, Joseph W Fay, et al.
British Journal of Haematology|April 2, 2019
Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 studyTorben Plesner, Hendrik-Tobias Arkenau, Francesca Gay, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 3, 2020
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTORMaria-Victoria Mateos, Pieter Sonneveld, Vania Hungria, et al.
Blood Advances|January 4, 2018
Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myelomaTineke Casneuf, Xu Steven Xu, Homer C Adams, et al.
Nature Microbiology|April 2, 2021
Detection of respiratory syncytial virus defective genomes in nasal secretions is associated with distinct clinical outcomesSébastien A Felt, Yan Sun, Agnieszka Jozwik, et al.
Nature Communications|June 11, 2026
Influenza coinfection inhibits control of mycobacterial infection in a human challenge modelClaire M Broderick, Oliver Powell, Sam Nichols, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 23, 2012
Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cellsGui-Mei Li, Christopher Chiu, Jens Wrammert, et al.
Science (New York, N.Y.)|October 9, 2020
Neutrophilic inflammation in the respiratory mucosa predisposes to RSV infectionMaximillian S Habibi, Ryan S Thwaites, Meiping Chang, et al.
Pageof 13

Showing results (61-70 of 129) with videos related to

Sort By:
Pageof 13
BMC Bioinformatics|March 8, 2020
CNV Radar: an improved method for somatic copy number alteration characterization in oncologyDavid Soong, Jeran Stratford, Herve Avet-Loiseau, et al.
Oncoimmunology|February 8, 2021
Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phagocytosisSerika D Naicker, Claire L Feerick, Kevin Lynch, et al.
Blood|June 23, 2017
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myelomaAjai Chari, Attaya Suvannasankha, Joseph W Fay, et al.
British Journal of Haematology|April 2, 2019
Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 studyTorben Plesner, Hendrik-Tobias Arkenau, Francesca Gay, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 3, 2020
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTORMaria-Victoria Mateos, Pieter Sonneveld, Vania Hungria, et al.
Blood Advances|January 4, 2018
Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myelomaTineke Casneuf, Xu Steven Xu, Homer C Adams, et al.
Nature Microbiology|April 2, 2021
Detection of respiratory syncytial virus defective genomes in nasal secretions is associated with distinct clinical outcomesSébastien A Felt, Yan Sun, Agnieszka Jozwik, et al.
Nature Communications|June 11, 2026
Influenza coinfection inhibits control of mycobacterial infection in a human challenge modelClaire M Broderick, Oliver Powell, Sam Nichols, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 23, 2012
Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cellsGui-Mei Li, Christopher Chiu, Jens Wrammert, et al.
Science (New York, N.Y.)|October 9, 2020
Neutrophilic inflammation in the respiratory mucosa predisposes to RSV infectionMaximillian S Habibi, Ryan S Thwaites, Meiping Chang, et al.
Pageof 13